A Study of Gaboxadol in Primary Insomnia
Phase 3
Completed
- Conditions
- Primary Insomnia
- Registration Number
- NCT00209963
- Lead Sponsor
- H. Lundbeck A/S
- Brief Summary
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Detailed Description
To obtain long-term safety and tolerability data with gaboxadol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- patients with Primary insomnia
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Long-term safety in gaboxadol.
- Secondary Outcome Measures
Name Time Method